Compare Digital Realty Trust, Inc. (DLR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Medpace Holdings Inc — how do they compare? Digital Realty Trust, Inc. trades at $177.1 (market cap $65.32B), while Medpace Holdings Inc trades at $613.31 (market cap $16.82B). The key difference: Digital Realty Trust, Inc. is far larger — about 3.9× Medpace Holdings Inc's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Medpace Holdings Inc for 14 Days on average.
| DLR | MEDP | |
|---|---|---|
Market Cap | $65.32B | $16.82B |
Volume | 2,563,950 | 223,093 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $630.19 |
52-Week Low | $147.93 | $393.42 |
Typical Hold Time | 94 Days | 14 Days |
Enterprise Value | $84.03B | $16.44B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $180.47, down 2.26% today, with a bearish technical signal despite strong analyst support. The data center REIT shows robust revenue growth to $6.11B in 2025 and expanding AI infrastructure partnerships, though valuation metrics remain elevated with a P/E of 85.89. Recent earnings show mixed results with Q2 2026 beating expectations by 150%.
DLR presents a compelling AI infrastructure play with strong growth prospects but faces valuation concerns and execution risks. The consensus price target of $222.35 suggests 23% upside potential, supported by 69% analyst buy ratings. Key risks include high leverage and competitive pressures in the rapidly expanding data center market.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
